skip to main content

Research + Education

The University of Michigan Rogel Cancer Center has a distinguished history of scientific excellence, collaboration and impact in basic science, clinical research and cancer control research.


  • Maria Castro inducted into the 2023 class of the AIMBE College of Fellows

    Maria G. Castro, Ph.D., R. C. Schneider Collegiate Professor of Neurosurgery and professor of cell and developmental biology at the University of Michigan, was inducted to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
    Read More >
  • Research shows some tumors grow after immunotherapy, but why?

    Immunotherapy has been a major advancement in cancer therapy, but it is not effective for all patients. In some instances, it can even cause tumors to “hyperprogress.” Researchers from the Rogel Cancer Center have found a mechanism for why a subset of patients’ tumors grow, rather than shrink, when faced with immunotherapy.
    Read More >
  • Swiecicki named associate medical director for Oncology Clinical Trials Support Unit

    Paul Swiecicki, M.D., has been named the inaugural associate medical director for the Oncology Clinical Trials Support Unit at the Rogel Cancer Center. The appointment was effective Jan. 1, 2023.
    Read More >
  • A new chapter for DEIJ at Rogel

    Diversity, equity, inclusion and justice are a crucial part of the Rogel Cancer Center’s mission, from Community Outreach and Engagement programs addressing health care disparities to hiring processes and leadership development. Now, diversity is a new requirement from the National Cancer Institute for its Cancer Center Support Grants, a chapter they refer to as the Plan to Enhance Diversity. In submitting the CCSG renewal last year, Rogel leadership provided a detailed outline of how we will support a diverse workforce.
    Read More >